Kirk S. Culotta

2.0k total citations
24 papers, 1.5k citations indexed

About

Kirk S. Culotta is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Kirk S. Culotta has authored 24 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Kirk S. Culotta's work include Cancer Treatment and Pharmacology (7 papers), Immune Cell Function and Interaction (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Kirk S. Culotta is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Immune Cell Function and Interaction (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). Kirk S. Culotta collaborates with scholars based in United States, Canada and Taiwan. Kirk S. Culotta's co-authors include Augusto C. Ochoa, Arnold H. Zea, Jovanny Zabaleta, Paulo C. Rodrı́guez, Juan B. Ochoa, Joanna DeSalvo, David Quiceno, Adel K. El‐Naggar, Vassiliki A. Papadimitrakopoulou and Claudia Patricia Pardo Hernández and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Kirk S. Culotta

24 papers receiving 1.5k citations

Peers

Countries citing papers authored by Kirk S. Culotta

Since Specialization

Citations

This map shows the geographic impact of Kirk S. Culotta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk S. Culotta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk S. Culotta more than expected).

Fields of papers citing papers by Kirk S. Culotta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirk S. Culotta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk S. Culotta. The network helps show where Kirk S. Culotta may publish in the future.

Co-authorship network of co-authors of Kirk S. Culotta

This figure shows the co-authorship network connecting the top 25 collaborators of Kirk S. Culotta. A scholar is included among the top collaborators of Kirk S. Culotta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirk S. Culotta. Kirk S. Culotta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma 2015 ·Molecular Cancer Therapeutics ·Salah-Eddine Lamhamedi-Cherradi, Brian A. Menegaz, Vandhana Ramamoorthy, (unknown), Rebecca L. Maywald, (unknown), (unknown), Kirk S. Culotta, (unknown), Joseph A. Ludwig	33
2	SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer 2015 ·JNCI Journal of the National Cancer Institute ·Ana M. González-Angulo, Ian E. Krop, Argun Akçakanat, Huiqin Chen, Shuying Liu, Yisheng Li, Kirk S. Culotta, Emily Tarco, Sarina A. Piha‐Paul, Stacy Moulder-Thompson, (unknown), Ayşegül A. Şahin, L. Austin Doyle, Kim‐Anh Do, Eric P. Winer, Gordon B. Mills, Razelle Kurzrock, Funda Meric‐Bernstam	30
3	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy 2015 ·Clinical Epigenetics ·Apostolia M. Tsimberidou, Rabih Said, Kirk S. Culotta, Ignacio I. Wistuba, Jaroslav Jelı́nek, Siqing Fu, Gerald S. Falchook, Aung Naing, Sarina A. Piha‐Paul, Ralph Zinner, Zahid H. Siddik, Guangan He, Kenneth R. Hess, David J. Stewart, Razelle Kurzrock, Jean‐Pierre J. Issa	14
4	Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases 2015 ·Cancer Chemotherapy and Pharmacology ·Siqing Fu, Kirk S. Culotta, Gerald S. Falchook, David S. Hong, Alan L. Myers, Yan-Ping Zhang, Aung Naing, Filip Jankú, Ming-Mo Hou, Razelle Kurzrock	6
5	Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors 2014 ·Cancer ·David S. Hong, Ignacio Garrido‐Laguna, Sühendan Ekmekçioğlu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Siqing Fu, Stacy L. Moulder, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, (unknown), Kirk S. Culotta, Kenna Anderes, Darren W. Davis, Wen Liu, Goldy C. George, Luis H. Camacho, Susan Percy Ivy, Razelle Kurzrock	25
6	A phase I study of the anti-IGF-1R monoclonal antibody (MoAb), IMC-A12 (I), and everolimus (E) in well-differentiated neuroendocrine tumors (WD NET). 2014 ·Journal of Clinical Oncology ·Arvind Dasari, Alexandria T. Phan, Sanjay Gupta, Kenneth R. Hess, Kirk S. Culotta, Asif Rashid, Sai‐Ching J. Yeung, Helen X. Chen, (unknown), Daniel M. Halperin, Ishwaria M. Subbiah, Funda Meric‐Bernstam, James C. Yao	1
7	Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion 2013 ·Journal of Oncology Pharmacy Practice ·Yanping Zhang, Jitesh D. Kawedia, Alan L. Myers, (unknown), Peter M. Anderson, Mark Kramer, Kirk S. Culotta	21
8	A Phase I/II Study Of Hyper-CVAD Plus Everolimus In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 2013 ·Blood ·Naval Daver, Hagop M. Kantarjian, Deborah A. Thomas, Michael Rytting, Farhad Ravandi, Nitin Jain, Jörge E. Cortes, Rebecca Garris, Mary Ann Richie, Marina Konopleva, Hongbo Hu, Jitesh D. Kawedia, Kirk S. Culotta, Susan O’Brien, (unknown), Lianchun Xiao, (unknown), Linda J. Bendall	4
9	Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. 2013 ·Journal of Clinical Oncology ·Shannon N. Westin, (unknown), Navdeep Pal, Diana L. Urbauer, Filip Jankú, Jennifer J. Wheler, Sarina A. Piha‐Paul, Aung Naing, Apostolia M. Tsimberidou, Siqing Fu, Gerald S. Falchook, David S. Hong, Ralph Zinner, Vivek Subbiah, Kirk S. Culotta, Karen H. Lu, Robert L. Coleman, Razelle Kurzrock	3
10	Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma 2012 ·Clinical Cancer Research ·Michael A. Davies, Patricia S. Fox, Nicholas E. Papadopoulos, Agop Y. Bedikian, Wen-Jen Hwu, Alexander J. Lazar, Víctor G. Prieto, Kirk S. Culotta, Timothy Madden, Quanyun A. Xu, Sha Huang, Wanleng Deng, Chaan S. Ng, Sanjay Gupta, Wenbin Liu, Janet Dancey, James R. Wright, Roland L. Bassett, Patrick Hwu, Kevin B. Kim	39
11	Busulfan and Metronidazole: An Often Forgotten but Significant Drug Interaction 2011 ·Annals of Pharmacotherapy ·Alison Gulbis, Kirk S. Culotta, Roy B. Jones, Börje S. Andersson	27
12	Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma 2010 ·Cancer ·(unknown), Bonnie S. Glisson, B. Nebiyou Bekele, Lawrence E. Ginsberg, Adel K. El‐Naggar, Kirk S. Culotta, Naoko Takebe, James R. Wright, Hai T. Tran, Vassiliki A. Papadimitrakopoulou	84
13	Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL). 2010 ·Blood ·Partow Kebriaei, Celina Ledesma, Kirk S. Culotta, Elizabeth J. Shpall, Stefan O. Ciurea, Amin M. Alousi, Marcos de Lima, Uday Popat, Deborah A. Thomas, Richard E. Champlin, Börje S. Andersson	1
14	Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions 2009 ·Cancer Prevention Research ·Anne S. Tsao, Diane Liu, Jack W. Martin, (unknown), J. Jack Lee, Adel K. El‐Naggar, Ignacio I. Wistuba, Kirk S. Culotta, Li Mao, Ann M. Gillenwater, Yuko M. Sagesaka, Waun Ki Hong, Vassiliki A. Papadimitrakopoulou	182
15	T cell CD3 receptor zeta (TCRζ)-chain expression in children with idiopathic nephrotic syndrome 2008 ·Pediatric Nephrology ·Diego Avilés, (unknown), Kirk S. Culotta, Jennifer Manning, Augusto C. Ochoa, Arnold H. Zea	6
16	The preclinical pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway 2006 ·Cancer Research ·Timothy Madden, (unknown), (unknown), Kirk S. Culotta, Nicholas J. Donato, Mary Johansen, Yasuko Kondo, David H. Mack, Waldemar Priebe	10
17	Decreased Expression of CD3ζ and Nuclear Transcription Factor κB in Patients with Pulmonary Tuberculosis: Potential Mechanisms and Reversibility with Treatment 2006 ·The Journal of Infectious Diseases ·Arnold H. Zea, Kirk S. Culotta, (unknown), Carol M. Mason, (unknown), Jovanny Zabaleta, Luis F. García, Augusto C. Ochoa	57
18	l-Arginine modulates CD3ζ expression and T cell function in activated human T lymphocytes 2004 ·Cellular Immunology ·Arnold H. Zea, Paulo C. Rodrı́guez, Kirk S. Culotta, Claudia Patricia Pardo Hernández, Joanna DeSalvo, Juan B. Ochoa, (unknown), Jovanny Zabaleta, Augusto C. Ochoa	175
19	l -Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes 2003 ·The Journal of Immunology ·Paulo C. Rodrı́guez, Arnold H. Zea, Joanna DeSalvo, Kirk S. Culotta, Jovanny Zabaleta, David Quiceno, Juan B. Ochoa, Augusto C. Ochoa	393
20	Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine 2002 ·Journal of Biological Chemistry ·Paulo C. Rodrı́guez, Arnold H. Zea, Kirk S. Culotta, Jovanny Zabaleta, Juan B. Ochoa, Augusto C. Ochoa	397

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact